Sanjeev Khindri Sells 4,134 Shares of Liquidia (NASDAQ:LQDA) Stock

Liquidia Corporation (NASDAQ:LQDA) insider Sanjeev Khindri sold 4,134 shares of the stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $65.46, for a total transaction of $270,611.64. Following the sale, the insider owned 67,132 shares in the company, valued at $4,394,460.72. This represents a 5.80% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Liquidia Price Performance

Shares of NASDAQ LQDA traded up $1.24 during trading hours on Wednesday, hitting $65.25. 2,327,936 shares of the stock were exchanged, compared to its average volume of 1,722,392. The company has a debt-to-equity ratio of 1.18, a quick ratio of 2.03 and a current ratio of 2.22. The company has a market cap of $5.80 billion, a PE ratio of 466.10 and a beta of 0.58. The company’s fifty day simple moving average is $47.90 and its two-hundred day simple moving average is $40.11. Liquidia Corporation has a 1-year low of $11.85 and a 1-year high of $66.78.

Liquidia (NASDAQ:LQDA) last posted its quarterly earnings results on Monday, May 11th. The company reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.41 by $0.11. The business had revenue of $132.87 million for the quarter, compared to analyst estimates of $119.44 million. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The business’s quarterly revenue was up 4187.1% compared to the same quarter last year. On average, sell-side analysts predict that Liquidia Corporation will post 2.97 EPS for the current year.

Hedge Funds Weigh In On Liquidia

A number of hedge funds have recently modified their holdings of LQDA. Farallon Capital Management LLC lifted its holdings in shares of Liquidia by 102.1% during the third quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company’s stock worth $194,783,000 after purchasing an additional 4,326,876 shares during the period. TCG Crossover Management LLC bought a new position in Liquidia during the third quarter worth $38,887,000. Caprock Group LLC bought a new position in Liquidia during the third quarter worth $37,114,000. MPM Bioimpact LLC raised its stake in Liquidia by 600.4% during the fourth quarter. MPM Bioimpact LLC now owns 1,400,869 shares of the company’s stock worth $48,316,000 after buying an additional 1,200,869 shares during the last quarter. Finally, Voloridge Investment Management LLC bought a new position in Liquidia during the third quarter worth $12,571,000. Institutional investors and hedge funds own 64.54% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have weighed in on LQDA. Wall Street Zen upgraded shares of Liquidia from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Liquidia in a research report on Tuesday, April 21st. Wells Fargo & Company raised their target price on shares of Liquidia from $51.00 to $62.00 and gave the company an “overweight” rating in a research report on Tuesday, May 12th. Zacks Research upgraded shares of Liquidia from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 5th. Finally, Raymond James Financial reiterated a “strong-buy” rating and set a $68.00 price target on shares of Liquidia in a report on Thursday, June 4th. Three analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Liquidia has a consensus rating of “Moderate Buy” and an average target price of $55.63.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).